Biomarkers for predicting postmenopausal coronary heart disease

Biomarkers in Medicine

Volumn 5, Issue 4, 2011, Pages 485-495

  Spoletini, Ilaria ^a   Vitale, Cristiana ^a   Rosano, Giuseppe M C ^a,b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b Centre for Clinical Research   (Italy)

Author keywords

atherosclerosis; biomarkers; coronary heart disease; dyslipidemia; hormone therapy; inflammation; menopause; oxidative stress

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIN 1; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; URIC ACID;

ACCURACY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; POSTMENOPAUSE; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; URIC ACID BLOOD LEVEL;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; LIPOPROTEIN(A); LIPOPROTEINS, HDL; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; URIC ACID;

EID: 80052051629     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.51     Document Type: Review

References (99)

1. Collins P, Rosano G, Casey C et al. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur. Heart J. 28, 2028-2040 (2007). (Pubitemid 47579557)
2. Rosano GM, Vitale C, Silvestri A, Fini M. Metabolic and vascular effect of progestins in post-menopausal women. Implications for cardioprotection. Maturitas 46(Suppl. 1), S17-S29 (2003). (Pubitemid 37506059)
3. Amant C, Holm P, Xu SH, Tritman N, Kearney M, Losordo DW Estrogen receptor-mediated, nitric oxide-dependent modulation of the immunologic barrier function of the endothelium: regulation of fas ligand expression by estradiol. Circulation 104, 2576-2581 (2001). (Pubitemid 33104796)
4. Salhotra S, Arora S, Anubhuti, Trivedi SS, Bhattacharjee J. Infuence of menopause on biochemical markers of endothelial dysfunction-A case-control pilot study in North Indian population. Maturitas 62, 166-170 (2009).
5. Arora S, Jain A, Chitra R. Effects of short-term hormone replacement therapy on atherogenic indices in Indian postmenopausal women. IJCB 21, 41-47 (2006).
6. Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119, 480-486, e21-e181 (2009).
7. Ulmer H, Kelleher CC, Fitz-Simon N, Diem G, Concin H. Secular trends in cardiovascular risk factors: an age-period cohort analysis of 698,954 health examinations in 181,350 Austrian men and women. J. Intern. Med. 261, 566-576 (2007). (Pubitemid 46835979)
8. Balkau B, Hu G, Qiao Q, Tuomilehto J, Borch-Johnsen K, Pyorala K. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE study. Diabetologia 47, 2118-2128 (2007). (Pubitemid 40174684)
9. Conroy RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 24, 987-1003 (2003). (Pubitemid 36712275)
10. Wilson PW, DAgostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 97, 1837-1847 (1998). (Pubitemid 28213628)
11. Khot UN, Khot MB, Bajzer CT et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290, 898-904 (2003). (Pubitemid 37430461)
12. Greenland P, Knoll MD, Stamler J et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 290, 891-897 (2003). (Pubitemid 37430460)
13. Biasillo G, Leo M, Della Bona R, Biasucci LM. Infammatory biomarkers and coronary heart disease: from bench to bedside and back. Intern. Emerg. Med. 5, 225-233 (2010).
14. Corson MA. Emerging infammatory markers for assessing coronary heart disease risk. Curr. Cardiol. Rep. 11, 452-459 (2009).
15. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J. Clin. Endocrinol. Metab. 88, 2470-2478 (2003). (Pubitemid 36724411)
16. Kaptoge S, Di Angelantonio E, Lowe G et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375, 132-140 (2010).
17. Zethelius B, Berglund L, Sundstrom J et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N. Engl. J. Med. 358, 2107-2116 (2008). (Pubitemid 351679597)
18. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107, 391-397 (2003).
19. Everett BM, Kurth T, Buring JE, Ridker PM. The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women. J. Am. Coll. Cardiol. 48, 2235-2242 (2006). (Pubitemid 44855447)
20. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann. Intern. Med. 145, 21-29 (2006). (Pubitemid 46780601)
21. May M, Lawlor DA, Brindle P, Patel R, Ebrahim S. Cardiovascular disease risk assessment in older women: can we improve on Framingham? British Women's Heart and Health prospective cohort study. Heart 92, 1396-1401 (2006). (Pubitemid 44578825)
22. Pischon T, Hu FB, Rexrode KM, Girman CJ, Manson JE, Rimm EB. Infammation, the metabolic syndrome, and risk of coronary heart disease in women and men. Atherosclerosis 197, 392-399 (2008). (Pubitemid 351273261)
23. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin. Chem. 47, 28-30 (2001).
24. Danesh J, Wheeler JG, Hirschfeld GM et al. C-reactive protein and other circulating markers of infammation in the prediction of coronary heart disease. N. Engl. J. Med. 350, 1387-1397 (2004). (Pubitemid 38419992)
25. Wang TJ, Gona P, Larson MG et al. Multiple biomarkers for the prediction of frst major cardiovascular events and death. N. Engl. J. Med. 355, 2631-2639 (2006). (Pubitemid 44969122)
26. Khera A, de Lemos JA, Peshock RM et al. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation 113, 38-43 (2006). (Pubitemid 43958486)
27. Kaski JC. C-reactive protein improves risk prediction in patients with acute coronary syndrome, or does it? Eur. Heart J. 31, 274-277 (2010).
28. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fbrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285, 2481-2485 (2001). (Pubitemid 32433842)
29. Silvestri A, Gebara O, Vitale C et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased infammatory response. Circulation 107, 3165-3169 (2003). (Pubitemid 36793086)
30. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 100, 713-716 (1999). (Pubitemid 29383640)
31. Pradhan AD, Manson JE, Rossouw JE et al. Infammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 288, 980-987 (2002). (Pubitemid 34920463)
32. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of infammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836-843 (2000). (Pubitemid 30165206)
33. Volpato S, Guralnik JM, Ferrucci L et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the Women's Health and Aging Study. Circulation 103, 947-953 (2001). (Pubitemid 32183799)
34. Vitale C, Gebara O, Mercuro G et al. Value of C-reactive protein levels and IL-6 in predicting events levels in women at increased cardiovascular risk. Maturitas 50, 239-246 (2005). (Pubitemid 40365026)
35. Mallat Z, Heymes C, Ohan J, Faggin E, Leseche G, Tedgui A. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler. Thromb. Vasc. Biol. 19, 611-616 (1999). (Pubitemid 29135162)
36. Szodoray P, Timar O, Veres K et al. TH1/TH2 imbalance, measured by circulating and intracytoplasmic infammatory cytokines-immunological alterations in acute coronary syndrome and stable coronary artery disease. Scand. J. Immunol. 64, 336-344 (2006). (Pubitemid 44215124)
37. Lakoski SG, Liu Y, Brosnihan KB, Herrington DM. Interleukin-10 concentration and coronary heart disease (CHD) event risk in the estrogen replacement and atherosclerosis (ERA) study Atherosclerosis 197, 443-447 (2008). (Pubitemid 351273266)
38. Poon M, Zhang X, Dunsky KG, Taubman MB, Harpel PC. Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation 96, 2514-2519 (1997). (Pubitemid 27451339)
39. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102, 1082-1085 (2000).
40. Shai I, Rimm EB, Hankinson SE et al. Lipoprotein (a) and coronary heart disease among women: beyond a cholesterol carrier? Eur. Heart J. 26, 1633-1639 (2005). (Pubitemid 41389694)
41. Bostom AG, Gagnon DR, Cupples LA et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation 90, 1688-1695 (1994). (Pubitemid 24320915)
42. Nguyen TT, Ellefson RD, Hodge DO, Bailey KR, Kottke TE, Abu-Lebdeh HS. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation 96, 1390-1397 (1997). (Pubitemid 27375327)
43. LaRosa JC. Lipids and cardiovascular disease: do the fndings and therapy apply equally to men and women? Women's Health Issues 2, 102-111, discussion 11-13 (1992).
44. Bittner V. Lipoprotein abnormalities related to women's health. Am. J. Cardiol. 90(8 Suppl.), 77-84 (2002).
45. Shai I, Rimm EB, Hankinson SE et al. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation 110, 2824-2830 (2004). (Pubitemid 39473604)
46. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Serum uric acid and 11.5-year mortality of middle-aged women: fndings of the Chicago Heart Association Detection Project in Industry. J. Clin. Epidemiol. 42, 257-267 (1989). (Pubitemid 19117031)
47. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann. Intern. Med. 131, 7-13 (1999). (Pubitemid 29310011)
48. Brand FN, McGee DL, Kannel WB, Stokes J 3rd, Castelli WP. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am. J. Epidemiol. 121, 11-18 (1985). (Pubitemid 15150683)
49. Simon JA, Lin F, Vittinghoff E, Bittner V. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: the Heart and Estrogen-progestin Replacement Study (HERS). Ann. Epidemiol. 16, 138-145 (2006). (Pubitemid 43197606)
50. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280, 605-613 (1998). (Pubitemid 28502636)
51. Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann. Epidemiol. 10, 136-143 (2000). (Pubitemid 30171270)
52. Jossa F, Farinaro E, Panico S et al. Serum uric acid and hypertension: the Olivetti Heart Study. J. Hum. Hypertens. 8, 677-681 (1994). (Pubitemid 24276965)
53. Strasak AM, Kelleher CC, Brant LJ et al. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. Int. J. Cardiol. 125, 232-239 (2008).
54. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res. (Hoboken) 62, 170-180 (2010).
55. Li Z, McNamara JR, Fruchart JC et al. Effects of gender and menopausal status on plasma lipoprotein subspecies and particle sizes. J. Lipid Res. 37, 1886-1896 (1996). (Pubitemid 26307669)
56. Vitale C, Marazzi G, Volterrani M, Aloisio A, Rosano G, Fini M. Metabolic syndrome. Minerva. Med. 97, 219-229 (2006). (Pubitemid 44483594)
57. Assmann G, Schulte H. The importance of triglycerides: results from the prospective cardiovascular munster (PROCAM) study. Eur. J. Epidemiol. 8(Suppl. 1), 99-103 (1992).
58. Carr MC, Kim KH, Zambon A et al. Changes in LDL density across the menopausal transition. J. Investig. Med. 48, 245-250 (2000).
59. Campos H, Genest JJ Jr, Blijlevens E et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler. Thromb. 12, 187-195 (1992).
60. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch. Intern. Med. 153, 2209-2216 (1993). (Pubitemid 23296487)
61. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk 3, 213-219 (1996). (Pubitemid 26266496)
62. Sakurai T, Iimuro S, Araki A et al. Age-associated increase in abdominal obesity and insulin resistance, and usefulness of AHA/NHLBI defnition of metabolic syndrome for predicting cardiovascular disease in Japanese elderly with type 2 diabetes mellitus. Gerontology 56, 141-149 (2010).
63. Lindheim SR, Presser SC, Ditkoff EC, Vijod MA, Stanczyk FZ, Lobo RA. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil. Steril. 60, 664-667 (1993). (Pubitemid 23298511)
64. Park Y W, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfeld SB. The metabolic syndrome: prevalence and associated risk factor fndings in the US population from the third national health and nutrition examination survey, 1988-1994. Arch. Intern. Med. 163, 427-436 (2003). (Pubitemid 36241019)
65. DiPietro L, Dziura J, Yeckel CW. Specifc relation between abdominal obesity and early-phase hyperglycemia is modulated by hepatic insulin resistance in healthy older women. Diabetes Care 33, 165-167 (2010).
66. Lee K. Usefulness of the metabolic syndrome criteria as predictors of insulin resistance among obese Korean women. Pub. Health Nutr. 13, 181-186 (2010).
67. Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Jarvinen H. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European group for the Study of insulin resistance (EGIR). Hypertension 30, 1144-1149 (1997).
68. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 59, 8-13 (1979). (Pubitemid 9082394)
69. Rosano GM, Vitale C, Fini M. Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system? Ann. NY Acad. Sci. 1092, 341-348 (2006). (Pubitemid 47092351)
70. Rosano GM, Vitale C, Tulli A. Managing cardiovascular risk in menopausal women. Climacteric 9(Suppl. 1), 19-27 (2006). (Pubitemid 44221806)
71. Lamon-Fava S, Herrington DM, Horvath K V, Schaefer EJ, Asztalos BF. Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status. Metabolism 59, 1794-1800 (2010).
72. Herrington DM, Reboussin DM, Klein KP et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Control Clin. Trials 21, 257-285 (2000). (Pubitemid 30259153)
73. Horter MJ, Sondermann S, Reinecke H et al. Associations of HDL phospholipids and paraoxonase activity with coronary heart disease in postmenopausal women. Acta. Physiol. Scand. 176, 123-130 (2002). (Pubitemid 35216289)
74. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 332, 73-78 (2006).
75. Siegel RD, Cupples A, Schaefer EJ, Wilson PW. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism 45, 1267-1272 (1996). (Pubitemid 26337674)
76. Gaspard U. Hyperinsulinaemia, a key factor of the metabolic syndrome in postmenopausal women. Maturitas 62, 362-365 (2009).
77. Pyorala K, Lehto S, De Bacquer D et al. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I and II surveys. Diabetologia 47, 1257-1265 (2004). (Pubitemid 39093321)
78. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin. Res. Cardiol. 95, 136-147 (2006).
79. Pradhan AD, Manson JE, Hendrix SL et al. Cross-sectional correlates of fasting hyperinsulinaemia in post-menopausal women of different ethnic origin. Diabet. Med. 23, 77-85 (2006).
80. Kip KE, Marroquin OC, Kelley DE et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the women's ischemia syndrome evaluation (WISE) study. Circulation 109, 706-713 (2004). (Pubitemid 38222888)
81. Marroquin OC, Kip KE, Kelley DE et al. Metabolic syndrome modifes the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the women's ischemia syndrome evaluation. Circulation 109, 714-721 (2004). (Pubitemid 38222889)
82. Vitale C, Fini M, Speziale G, Chierchia S. Gender differences in the cardiovascular effects of sex hormones. Fundam. Clin. Pharmacol. 24, 675-685 (2010).
83. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21, 1011-1153 (2003).
84. Waters DD, Alderman EL, Hsia J et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 288, 2432-2440 (2002). (Pubitemid 35340539)
85. Ruo B, Tripputi MT, Hsue PY, Saigo M, Ouyang P, Waters DD. Usefulness of serum endothelin levels in predicting death and myocardial infarction but not coronary progression in postmenopausal women with coronary disease (from the Women's Angiographic Vitamin and Estrogen [WAVE] study). Am. J. Cardiol. 96, 335-338 (2005). (Pubitemid 41058854)
86. Cerquetani E, Vitale C, Mercuro G, Fini M, Zoncu S, Rosano GM. Comparative vascular effects of hormone replacement therapy and raloxifene in women at increased cardiovascular risk. Gynecol. Endocrinol. 18, 291-298 (2004). (Pubitemid 38916350)
87. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA 297, 611-619 (2007).
88. Wenger NK. The Reynolds risk score: improved accuracy for cardiovascular risk prediction in women? Nat. Clin. Prac. Cardiovasc. Med. 4, 366-367 (2007). (Pubitemid 47023441)
89. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefts of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002). (Pubitemid 34761611)
90. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291, 1701-1712 (2004). (Pubitemid 38489892)
91. Manson JE, Hsia J, Johnson KC et al. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. 349, 523-534 (2003). (Pubitemid 36951364)
92. Bray PF, Larson JC, Lacroix AZ et al. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am. J. Cardiol. 101, 1599-1605 (2008).
93. Kim HC, Greenland P, Rossouw JE et al. Multimarker prediction of coronary heart disease risk: the Women's Health Initiative. J. Am. Coll. Cardiol. 55, 2080-2091 (2010).
94. Rossouw JE. Prescribing postmenopausal hormone therapy to women in their 50s in the post-Women's Health Initiative era. Maturitas 65, 179-180 (2010).
95. Sever P. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT): testing C-reactive protein at baseline and on-treatment as an independent predictor of cardiovascular outcomes. Presented at: American Heart Association 2010 Scientifc Sessions. Chicago, IL, USA, 17 November 2010 (Late-breaking clinical trials IV).
96. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008).
97. Shah T, Casas JP, Cooper JA et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int. J. Epidemiol. 38, 217-231 (2009).
98. Folsom AR, Chambless LE, Ballantyne CM et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch. Intern. Med. 166, 1368-1373 (2006). (Pubitemid 44036348)
99. Kastrup J, Johansen JS, Winkel P et al. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur. Heart J. 30, 1066-1072 (2009).